{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:59:17Z","timestamp":1740178757926,"version":"3.37.3"},"reference-count":10,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T00:00:00Z","timestamp":1559779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2016-01527"],"award-info":[{"award-number":["2016-01527"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Swedish state under the Agreement between the Swedish government and the county councils (the ALF-agreement)","doi-asserted-by":"publisher","award":["2018-04276"],"award-info":[{"award-number":["2018-04276"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["9321-430"],"award-info":[{"award-number":["9321-430"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008550","name":"Diabetesfonden","doi-asserted-by":"publisher","award":["2017-205"],"award-info":[{"award-number":["2017-205"]}],"id":[{"id":"10.13039\/501100008550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["20120533"],"award-info":[{"award-number":["20120533"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","award":["2017.0203"],"award-info":[{"award-number":["2017.0203"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In female-to-male transgender individuals, testosterone is used to induce masculinization. Sex steroid therapy may increase circulating triglyceride and low-density lipoprotein cholesterol (LDL-C) levels and may decrease high-density lipoprotein cholesterol (HDL-C) levels, resulting in a more atherogenic lipid profile. These potentially adverse effects of androgen therapy may be exacerbated by the presence of familial hypercholesterolemia (FH). We describe the case of a transgender man with genetically diagnosed FH who was intolerant to statins and was started on a proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitor to control his lipoproteins more effectively.<\/jats:p>\n               <jats:p>The 35-year-old female-to-male transgender individual was referred to our center with a history of elevated LDL-C levels. Despite treatment with high doses of high-potency statins and ezetimibe, he had never achieved a sustained reduction in LDL-C; his levels of LDL-C were fluctuating between 170 and 344 mg\/dL (4.4 and 8.9 mmol\/L). Moreover, he developed side effects to statins in the form of myalgia and discontinued statin treatment. At the Sahlgrenska Lipid Clinic, a genetic diagnosis of heterozygous FH was established, and PCSK9 inhibitor therapy was started. The patient\u2019s LDL-C level has been reduced by approximately 40% for 23 months, and no adverse events have been reported.<\/jats:p>","DOI":"10.1210\/js.2019-00070","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T09:05:55Z","timestamp":1559811955000},"page":"1461-1464","source":"Crossref","is-referenced-by-count":1,"title":["PCSK9 Inhibitors in a Statin-Intolerant Transgender Man With Heterozygous Familial Hypercholesterolemia: A Case Report"],"prefix":"10.1210","volume":"3","author":[{"given":"Carlo","family":"Pirazzi","sequence":"first","affiliation":[{"name":"Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden"},{"name":"Cardiology Department, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1720-4355","authenticated-orcid":false,"given":"Federica","family":"Tavaglione","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c5sa","family":"Tivesten","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden"},{"name":"Wallenberg Laboratory for Cardiovascular and Metabolic Research, Institute of Medicine, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden"},{"name":"Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Romeo","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden"},{"name":"Cardiology Department, Sahlgrenska University Hospital, Gothenburg, Sweden"},{"name":"Clinical Nutrition Unit, Department of Medical and Surgical Sciences, University Magna Graecia, Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2019,6,6]]},"reference":[{"issue":"12","key":"2019073009501607200_bib1","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.4158\/1934-2403-23.12.1437","article-title":"T\u2019Sjoen GG. Endocrine treatment of gender-dysphoric\/gender-incongruent persons: an Endocrine Society clinical practice guideline","volume":"23","author":"Hembree","year":"2017","journal-title":"Endocr Pract"},{"issue":"5","key":"2019073009501607200_bib2","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/andr.12382","article-title":"Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review","volume":"5","author":"Velho","year":"2017","journal-title":"Andrology"},{"issue":"11","key":"2019073009501607200_bib3","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1210\/jc.2017-01643","article-title":"Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis","volume":"102","author":"Maraka","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"22","key":"2019073009501607200_bib4","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"issue":"4","key":"2019073009501607200_bib5","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/joim.12263","article-title":"Genetic diagnosis of familial hypercholesterolaemia by targeted next-generation sequencing","volume":"276","author":"Maglio","year":"2014","journal-title":"J Intern Med"},{"issue":"2","key":"2019073009501607200_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1034\/j.1399-0004.2000.570205.x","article-title":"Molecular genetic testing for familial hypercholesterolemia: spectrum of LDL receptor gene mutations in the Netherlands","volume":"57","author":"Lombardi","year":"2000","journal-title":"Clin Genet"},{"issue":"1","key":"2019073009501607200_bib7","doi-asserted-by":"crossref","first-page":"17093","DOI":"10.1038\/nrdp.2017.93","article-title":"Familial hypercholesterolaemia","volume":"3","author":"Defesche","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"18","key":"2019073009501607200_bib8","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"2019073009501607200_bib9","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"2019073009501607200_bib10","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/js.2019-00070\/28768646\/js.2019-00070.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jes\/article-pdf\/3\/8\/1461\/29017654\/js.2019-00070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T00:39:40Z","timestamp":1569112780000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/3\/8\/1461\/5511565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,6]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/js.2019-00070","relation":{},"ISSN":["2472-1972"],"issn-type":[{"type":"electronic","value":"2472-1972"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2019,6,6]]}}}